Innate ends work on NK cell engager in phase 1/2 trial as part of ongoing pipeline refocus
Fuente:
FierceBiotech
Innate Pharma has finally called time on an NK cell engager in phase 1/2 development as part of an ongoing fine-tuning of the French biotech’s pipeline.